Clinical Trial

Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis

Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The primary purpose of this study is to determine whether the drug sirolimus reduces the likelihood of developing of pulmonary fibrosis in patients who are hospitalized with COVID-19 pneumonia.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2021-06-29; most recent amendment 2025-12-05.
Status change: Recruiting → Active, Not Recruiting 2025-08-12
Status change: Not Yet Recruiting → Recruiting 2021-07-09
Trial Details
NCT Number NCT04948203
Lead Sponsor University of Chicago
Conditions Pulmonary Fibrosis, COVID-19 Pneumonia, Long COVID
Enrollment 60 participants
Start Date 2021-07-09
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-15